Menu Search
Equities

Cartesian Therapeutics Inc

1S7:STU

Cartesian Therapeutics Inc

Actions
  • Price (EUR)13.24
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-52.28%
  • Beta--
Data delayed at least 15 minutes, as of Apr 04 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

  • Revenue in USD (TTM)26.00m
  • Net income in USD-219.71m
  • Incorporated2007
  • Employees38.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		RNAC:NMQ since
announced		Transaction
value
Cartesian Therapeutics IncDeal completed13 Nov 202313 Nov 2023Deal completed-10.41%6.81m
Data delayed at least 15 minutes, as of May 06 2024 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.